Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of IBB0979 in Advanced Solid Tumors
NCT05991583Phase 2Recruiting
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Jul 2023
- Primary completion
- Nov 2025
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of IBB0979 in solid tumor (advanced stage), sponsored by SUNHO BioPharmaceutical. Started Jul 2023; status: recruiting.
02
Drugs
IBB0979
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05991583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05991583.